IP Library Granted Patent US 8,415,123
Granted Patent B2
US 8,415,123 · App. 12/661,377 · Granted Apr 9, 2013

Electromagnetic treatment apparatus and method for angiogenesis modulation of living tissues and cells

Inventors: Arthur A. Pilla (Oakland, NJ); Andre′ A. DiMino (Woodcliff Lake, NJ)
Assignee: Ivivi Health Sciences, LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,415,123
App. No.
12/661,377
Granted
Apr 9, 2013
Kind
B2
Abstract

An apparatus and method for electromagnetic treatment of living tissues and cells comprising: configuring at least one waveform according to a mathematical model having at least one waveform parameter, said at least one waveform to be coupled to a angiogenesis and neovascularization target pathway structure; choosing a value of said at least one waveform parameter so that said at least waveform is configured to be detectable in said angiogenesis and neovascularization target pathway structure above background activity in said target pathway structure; generating an electromagnetic signal from said configured at least one waveform; and coupling said electromagnetic signal to said angiogenesis and neovascularization target pathway structure using a coupling device.

Claims (32)

1. A method for electromagnetic treatment of living tissues and cells by enhancing angiogenesis and neovascularization comprising the steps of:

applying a portable electromagnetic treatment device adjacent to a target tissue site;

generating an electromagnetic signal from at least one waveform; and

coupling said electromagnetic signal to said angiogenesis and neovascularization target pathway structure using a coupling device; and

inducing an electromagnetic field at the target tissue site from the at least one waveform, wherein said at least one waveform is configured to be coupled to an angiogenesis and neovascularization target pathway structure at the target tissue site by modulating binding of calcium to Calmodulin, wherein the waveform induces a power that is greater than the thermal noise power of calcium binding to Calmodulin so that the at least one waveform is configured to be detectable in said angiogenesis and neovascularization target pathway structure above background activity in said angiogenesis and neovascularization target pathway structure.

2. The method of claim 1 , wherein said at least one waveform comprises at least one of a frequency component parameter that configures said at least one waveform to repeat between about 0.01 Hz and about 100 MHz, a burst amplitude envelope parameter that follows a mathematically defined amplitude function, a burst width parameter that varies at each repetition according to a mathematically defined width function, a peak induced electric field parameter varying between about 1 μV/cm and about 100 mV/cm in said target pathway structure according to a mathematically defined function, and a peak induced magnetic field parameter varying between about 1 and about 0.1 T in said target pathway structure according to a mathematically defined function.

3. The method of claim 1 , wherein said angiogenesis and neovascularization target pathway structure includes the binding of at least one of ions and ligands.

4. The method of claim 1 , wherein said inducing an electromagnetic field at the target tissue site comprises modulating growth factor production in living cells and tissues.

5. The method of claim 1 , wherein said inducing an electromagnetic field at the target tissue site comprises modulating cytokine production in living cells and tissues.

6. The method of claim 1 , wherein said inducing an electromagnetic field at the target tissue site comprises modulating growth factors and cytokines relevant to angiogenesis and neovascularization.

7. The method of claim 1 , wherein said inducing an electromagnetic field at the target tissue site comprises modulating angiogenesis and neovascularization for treatment of bone fractures and disorders.

8. The method of claim 1 , wherein said inducing an electromagnetic field at the target tissue site comprises modulating angiogenesis and neovascularization for treatment of cardiovascular diseases.

9. The method of claim 1 , wherein said inducing an electromagnetic field at the target tissue site comprises modulating angiogenesis and neovascularization for treatment of cerebral diseases.

10. The method of claim 1 , wherein said inducing an electromagnetic field at the target tissue site comprises modulating angiogenesis and neovascularization for treatment of cerebrovascular disease.

11. The method of claim 1 , wherein said inducing an electromagnetic field at the target tissue site comprises modulating angiogenesis and neovascularization for treatment peripheral vascular disease.

12. The method of claim 1 , wherein said inducing an electromagnetic field at the target tissue site comprises modulating angiogenesis and neovascularization for treatment of diseased or ischemic cells and tissues.

13. The method of claim 1 , wherein said inducing an electromagnetic field at the target tissue site comprises modulating angiogenesis and neovascularization for treatment of an acute or chronic soft tissue wound.

14. The method of claim 1 , wherein said inducing an electromagnetic field at the target tissue site comprises modulating angiogenesis and neovascularization for treatment of sprains strains and contusions.

15. The method of claim 1 , wherein the at least one waveform comprises frequency components for coupling to an impedance of the binding of calcium to Calmodulin and thus the angiogenesis and neovascularization target pathway.

16. The method of claim 15 , wherein the at least one waveform comprises frequency components that fall within the bandpass of the kinetics of binding of calcium to Calmodulin.

17. The method of claim 1 , wherein generating the electromagnetic signal comprises generating a burst of arbitrary waveforms having a plurality of frequency components ranging from about 0.01Hz to about 100 MHz, the plurality of frequency components satisfying a SNR or PSNR model for the angiogenesis and neovascularization target pathway structure.

18. The method of claim 1 , wherein the induced electromagnetic field comprises a burst duration between about 10 msec to about 100 msec.

19. The method of claim 1 , wherein the induced electromagnetic field comprises a peak amplitude between about 1 μV/cm and about 100 mV/cm.

20. The method of claim 1 , wherein the at least one waveform has a frequency of approximately 27.12 MHz.

21. The method of claim 1 , wherein generating the electromagnetic signal comprises applying a treatment regime so that the electromagnetic signal is applied according to the treatment regimen.

22. The method of claim 21 , wherein the treatment regimen applies the electromagnetic signal for a total time of under 1 minute to 240 minutes daily.

23. The method of claim 1 , wherein the electromagnetic signal comprises a duty cycle of between about 1 to about 10 −5 .

24. A method for electromagnetic treatment of living tissues and cells by enhancing angiogenesis and neovascularization comprising the steps of:

applying a portable electromagnetic treatment device adjacent to a target tissue site;

generating an electromagnetic signal from at least one waveform; and

coupling said electromagnetic signal to said angiogenesis and neovascularization target pathway structure using a coupling device; and

inducing an electromagnetic field at the target tissue site from the at least one waveform, wherein said at least one waveform is configured to be coupled to an angiogenesis and neovascularization target pathway structure at the target tissue site, wherein the waveform is further configured to have a time constant that matches the bandpass of calcium binding to Calmodulin according to an electrically equivalent model of calcium binding to Calmodulin, and wherein the waveform is configured to induce a power at the target tissue that is greater than the thermal noise power of calcium binding to Calmodulin.

Assignments (9)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 9, 2024
From: ENDONOVO THERAPEUTICS, INC.
To: SOFPULSE, INC.
Reel/Frame 067933/0673 →
LICENSE Recorded Sep 24, 2019
From: RIO GRANDE NEUROSCIENCES, INC., ASSIGNOR TO ENDONOVO THERAPEUTICS INC.
To: AAH HOLDINGS LLC
Reel/Frame 050475/0809 →
SECURITY AGREEMENT Recorded Feb 1, 2018
From: ENDONOVO THERAPEUTICS, INC.
To: STEVEN M. GLUCKSTERN
Reel/Frame 045221/0863 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 17, 2018
From: RIO GRANDE NEUROSCIENCES, INC.
To: ENDONOVO THERAPEUTICS INC.
Reel/Frame 044644/0182 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 5, 2016
From: IVIVI HEALTH SCIENCES, LLC
To: RIO GRANDE NEUROSCIENCES, INC.
Reel/Frame 037445/0365 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 28, 2015
From: IVIVI HEALTH SCIENCES, LLC
To: RIO GRANDE NEUROSCIENCES, INC.
Reel/Frame 037394/0244 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 26, 2012
From: PILLA, ARTHUR A.; DIMINO, ANDRE' A.
To: IVIVI TECHNOLOGIES, INC.
Reel/Frame 028650/0745 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 26, 2012
From: IVIVI TECHNOLOGIES, INC.
To: IVIVI TECHNOLOGIES, LLC
Reel/Frame 028650/0777 →
CHANGE OF NAME Recorded Jul 26, 2012
From: IVIVI TECHNOLOGIES, LLC
To: IVIVI HEALTH SCIENCES, LLC
Reel/Frame 028650/0809 →
Continuity (3)
Division 11110000 · Apr 19, 2005
Provisional Application 60563104 · Apr 19, 2004
Related Publication 20100179373A1 · Jul 15, 2010